Related Experiment Video

Updated: Aug 19, 2026

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

Multiple forms of monoamine oxidase in chronic schizophrenia

S A Al-Mudhaffar, N M Fahad

    Biochemistry and Experimental Biology
    |January 1, 1979
    PubMed

    More Related Videos

    A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices07:56

    A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

    Published on: August 11, 2021

    Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra05:14

    Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

    Published on: September 8, 2021

    Related Concept Videos

    Drugs Affecting Neurotransmitter Release or Uptake01:21

    Drugs Affecting Neurotransmitter Release or Uptake

    Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
    Drugs Affecting Neurotransmitter Synthesis01:29

    Drugs Affecting Neurotransmitter Synthesis

    Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
    Antidepressant Drugs: MAOIs and Other Agents01:23

    Antidepressant Drugs: MAOIs and Other Agents

    Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
    Negative and Cognitive Symptoms of Schizophrenia01:30

    Negative and Cognitive Symptoms of Schizophrenia

    Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
    Negative Symptoms
    Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
    Biological Causes of Schizophrenia01:29

    Biological Causes of Schizophrenia

    Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
    Genetic Factors in Schizophrenia
    The genetic basis of schizophrenia is strongly supported by family and twin studies.
    Parkinson Disease ll: Pathophysiology01:24

    Parkinson Disease ll: Pathophysiology

    Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...